Within the Section 3 LEAP-012 trial, KEYTRUDA plus LENVIMA together with TACE decreased the chance of illness development or demise…
Our selection of the week's biggest research news and features sent directly to your inbox. Enter your email address, confirm you're happy to receive our emails.
Please contact salesdepartment
for further information at:
Sales@88.broker
Sign in to your account